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Abstract
Kaposi sarcoma-associated herpesvirus (KSHV, also called Human herpesvirus 8 or HHV8) is a g-2 herpesvirus that
causes Kaposi sarcoma. KSHV seroprevalence rates vary geographically with variable rates recorded in different sub
Sahara African countries, suggesting that effects of genetic and/or environmental factors may influence the risk of
infection. One study conducted in South Africa, where KSHV seroprevalence is relatively low, found that carriage of
human leukocyte antigen (HLA) alleles HLA-A*6801, HLA-A*30, HLA-A*4301, and HLA-DRB1*04 was associated with
increased shedding of KSHV DNA in saliva. Confirmation of those results would strengthen the hypothesis that
genetic factors may influence KSHV distribution by modulating KSHV shedding in saliva. To explore these
associations in another setting, we used high resolution HLA-A, B, and DRB1 typing on residual samples from the
Uganda Sickle Cell Anemia KSHV study, conducted in a high KSHV seroprevalence region, to investigate
associations between HLA and KSHV shedding in saliva or peripheral blood among 233 children and their mothers.
HLA-A and HLA-DRB1 alleles were not associated with KSHV shedding in our study, but our study was small and
was not adequately powered to exclude small associations. In exploratory analyses, we found marginal association
of KSHV DNA shedding in saliva but not in peripheral blood among children carrying HLA- B*4415 and marginal
association of KSHV DNA shedding in peripheral blood but not in saliva among children carrying HLA- B*0801
alleles. The contribution of individual HLA polymorphisms to KSHV shedding is important but it may vary in
different populations. Larger population-based studies are needed to estimate the magnitude and direction of
association of HLA with KSHV shedding and viral control.
Findings
Kaposi sarcoma-associated herpesvirus (KSHV, also
called Human herpesvirus 8 or HHV8) is a g-2 herpes-
virus etiologically linked to Kaposi sarcoma (KS) [1].
KSHV seroprevalence in the general population is high-
est in sub-Saharan Africa (50-60%), intermediate in
South America and the Mediterranean countries
(10-40%), and low in Europe and North America (< 5%)
[2], suggesting that genetic and/or environmental factors
may influence KSHV seropositivity patterns [3,4]. Envir-
onmental factors, including plants in regions of Africa
where KSHV prevalence and KS incidence are high,
have been postulated to influence KSHV lytic replication
and, thus, increase KSHV shedding [5]. Colluzi et al.,
speculated that KSHV transmission is increased indir-
ectly when KSHV infected saliva is used to soothe itchy
insect bites caused by blood-sucking arthropods [6]. The
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of a major recessive gene on KSHV susceptibility or
resistance to KSHV infection was postulated, based on
statistical analysis of familial clustering of KSHV infec-
tion, among Noire-Marrons families in French Guiana
[7]. Recently, a study in South Africa found increased
KSHV DNA shedding in saliva among subjects carrying
human leukocyte antigens (HLA) HLA-A*6801, HLA-
A*30, HLA-A*4301, and HLA-DRB1*04 alleles [8].
Given that HLA polymorphisms have been shown to
influence transmission, control, and pathogenesis of
other viral infections such as human papillomavirus,
human immunodeficiency virus type 1 and human
T cell lymphotropic virus type 1 [9-11], this finding is
biologically plausible. Thus, we sought to replicate the
findings from South Africa in Uganda and to explore
novel HLA allele associations with KSHV shedding
using residual samples and data from the Uganda Sickle
Cell Anemia KSHV study [12].
The Uganda Sickle Cell Anemia KSHV study included
600 children with sickle cell anemia, but without KS,
who were enrolled from November 2001 to April 2002
at the Sickle Cell Clinic at Mulago Hospital [12]. The
mothers of the children were also included when avail-
able. Children were confirmed by gel electrophoresis to
have sickle cell anemia (homozygous for the sickle cell
gene) and the mothers were presumed to have the sickle
cell trait (heterozygous for the sickle cell gene), but not
sickle cell anemia. Children and their mothers were
tested serologically for anti-KSHV antibodies using two
peptide enzyme immunoassays (EIA) to the K8.1 and
ORF73 KSHV peptides, as previously described [12].
A subset of 233 children, including 183 who were
KSHV seropositive on either the K8.1 or the ORF73 EIA
and 50 children randomly selected from among 417
children who were seronegative on both assays, were
further studied for KSHV viral shedding in saliva and in
peripheral blood using quantitative polymerase chain
reaction (qPCR) for KSHV DNA [3].
We performed high-resolution HLA-A, -B and -DRB1
typing on residual DNA obtained from saliva or buffy
coat of the children and their mothers from the KSHV
viral study. Alleles were separated by a group-specific
amplification approach using multiple amplification pri-
mer mixes in parallel (PROTRANS S3/S4 HLA SINGLE
ALLELE SEQUENCING SET, PROTRANS MEDICAL
DIAGNOSTICS, HOCKENHEIM, GERMANY) [13].
The presence or absence of a PCR product was demon-
strated by an agarose gel-based read-out for HLA-A and
HLA-B while the PCR product detection for HLA-DRB1
was achieved by fluorescence-based read-out using the
5’ nuclease technology [14]. Purification of the PCR pro-
duct was performed enzymatically by exonuclease/
shrimp alkaline phosphatase treatment (ExoSAP-IT;
USB; Cleveland, OH, USA), followed by forward and
reverse sequencing of exon 2 and 3 for HLA class I and
of exon 2 for HLA class II, using Big Dye Terminator
Technology (Applied Biosystems, Foster City, CA, USA).
The sequencing reaction products were purified using
the Montage SEQ96 sequencing reaction cleanup kit
(Millipore, Billerica, MA, USA) and subjected to electro-
phoresis on a 3730 Genetic Analyzer (Applied Biosys-
tems). The data were analyzed using the Sequence Pilot
program (version 3.0; Protrans). Sequencing-based typ-
ing allowed determination of HLA allele groups on basis
of resolution at the 2- digit level and alleles on basis of
resolution at the 4-digit level [8].
We calculated the weighted distribution of HLA-A, -B,
and -DRB1 allele group frequencies among the children
and their mothers separately. The prevalence of allele
groups was weighted back to the original study popula-
tion. Thus, the weighted prevalence of HLA allele group
(X) in the children = (prevalence of allele group X in
KSHV-negative children × proportion of children who
were KSHV negative) + (prevalence of allele group X in
KSHV-positive children X proportion of children who
were KSHV positive). The prevalence of HLA allele
groups for the mothers was weighted back to the origi-
nal study population based on KSHV status of the chil-
dren because the mothers were selected when their
child was selected.
We assessed associations between HLA allele groups
and KSHV DNA detection for the alleles selected a
priori based on previous associations with KSHV shed-
ding in saliva: HLA-A*6801, HLA-A*30 and HLA-
A*4301, and HLA-DRB1*04 separately for the children
and their mothers. We also performed exploratory ana-
lyses to identify new associations. Odds ratios (ORs) for
association and corresponding 95% confidence intervals
(95% CIs) were computed using logistic regression mod-
els. We adjusted for KSHV serostatus by including the
posterior probability of KSHV infection estimated using
multivariate mixture models as previously described
[15]. All statistical tests were two-sided and p-values <
0.05 were considered statistically significant.
Among 233 children with DNA, HLA was success-
fully typed for the A locus in 223, for the B locus in
225, for the DRB1 locus in 223 children. Among 233
mothers with DNA, HLA was successfully typed for
the A locus in 226, for the B locus in 226, for the
DRB1 locus in 227 mothers. The weighted prevalence
for HLA loci, HLA-A, -B, and -DRB1 and the number
of people carrying the allele group for children and
their mothers separately are shown in Table 1. The
allele group distribution between mothers and children
for HLA-A, -B, and -DRB1 were similar (Table 1). For
each locus, the 4 most frequent allele groups were
HLA-A*02, A*30, A*68, A*74; B*58, B*53, B*15, B*42;
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Page 2 of 5and DRB1*11, DRB1*15, DRB1*13, DRB1*01 among
the children and HLA-A*02, A*30, A*68, A*23; B*58,
B*45, B*15, B*42; and DRB1*11, DRB1*15, DRB1*13,
DRB1*03 among the mothers. HLA-A*43, which was
associated with KSHV shedding in South Africa, was
not observed in our study. HLA-DRB1*04 allele group
was observed in only 1% of the children and in only
2% of the mothers.
HLA-A*3001, HLA-A*3002, HLA-A*6801, HLA-
A*6802, and DRB1*0405 alleles were not associated with
detection of KSHV DNA in saliva or in peripheral blood
in the children (Table 2) or in the mothers (results not
Table 1 Weighted* HLA allele group prevalence among children and mothers in the Uganda Sickle Cell Anemia KSHV
Study, 2001-2002
Children Women
HLA group Number
typed†
Percent positive for allele group
(number positive)
Number
typed†
Percent positive for allele
group (number positive)
p-value ‡
HLA-A 223 226
*01 5.1 (22) 3.5 (22)
*02 19.5 (82) 20.0 (78)
*03 5.2 (23) 4.6 (28)
*23 10.2 (42) 8.8 (38)
*29 5.0 (32) 7.3 (37)
*30 12.0 (75) 13.7 (82)
*36 5.4 (13) 5.2 (13)
*66 5.0 (26) 8.0 (36)
*68 11.5 (39) 10.6 (43)
*74 10.7 (38) 6.2 (31)
0.94
HLA-B 225 225
*07 4.9 (18) 6.2 (18)
*08 3.4 (18) 3.1 (15)
*15 10.5 (59) 9.0 (65)
*42 6.8 (35) 8.9 (40)
*44 3.9 (14) 3.1 (16)
*45 8.0 (32) 11.9 (41)
*49 1.5 (13) 5.3 (16)
*53 11.6 (40) 8.7 (36)
*57 5.9 (21) 2.1 (22)
*58 16.6 (59) 16.8 (73)
*82 6.1 (6) 0.1 (2)
0.98
HLA-DRB1 223 227
*01 10.5 (48) 8.0 (37)
*03 9.4 (56) 10.1 (59)
*04 1.0 (4) 1.7 (4)
*07 6.5 (31) 5.8 (37)
*08 5.0 (20) 5.6 (20)
*11 28.2 (113) 28.8 (116)
*12 3.7 (11) 6.1 (17)
*13 11.7 (68) 12.3 (59)
*15 15.9 (61) 14.4 (70)
0.95
* For both children and their mothers prevalence for HLA-A, -B, -DRB1 allele groups was weighted according to KSHV serostatus of the children (the selection
criteria for inclusion in the study) using the formula: weighted prevalence (a) of HLA allele group X in the children (or mothers) = (Prevalence of X in KSHV
negative children (or mothers) × proportion of KSHV negative children) + (Prevalence of X in KSHV positive children (or mothers) × Prevalence of KSHV positive
children). See methods in text for details.
† Total is less than 233 because fewer subjects were successfully typed for HLA-A, -B and -DRB1.
‡ P-value for heterogeneity comparing HLA-A, -B and -DRB1 allele group distribution between mothers and children.
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DNA in saliva among children carrying at least 1 HLA-
B*4415 allele (OR 5.5; 95% CI 1.1-28.6), but the risk was
not increased for detecting KSHV DNA in peripheral
blood (OR 1.1; 95% CI 0.1-9.2). We found increased risk
of detectable KSHV DNA in peripheral blood in chil-
dren carrying at least 1 HLA- B*0801 allele (OR 3.9;
95% CI 1.4-10.8), but the risk was not increased for
detecting KSHV DNA in saliva (OR 1.1; 95% CI 0.3-4.1).
Our study did not replicate HLA associations with
KSHV DNA shedding reported in South Africa [8]. Our
null results are likely due to the small size of our study
and hence limited power to demonstrate weak associa-
tions. Another reason is that, our study included a
highly selected group of children, i.e., with sickle cell
anemia and their mothers with sickle cell trait, who may
be systematically different in their HLA genotype distri-
bution from the general population. In addition, because
KSHV shedding is often intermittent, associations
between KSHV shedding and HLA may have been
missed by our study that relied on peripheral blood and
saliva, taken at one time point. We found that the distri-
butions of HLA allele groups in the mothers and
children were similar and resembled the distributions of
HLA allele groups in two general population-based stu-
dies in Uganda [16,17] suggesting that the selected nat-
u r eo fo u rp o p u l a t i o nm a yn o tb eam a j o rr e a s o nf o r
our null results. Possibly, different alleles influence
KSHV shedding in different populations, as suggested by
the rare-allele advantage model [18]. The polymorphic
nature of HLA is critical for conferring diverse and
effective pathogen response. Because polymorphisms in
HLA are influenced by pathogens that are common in
the environment where the population resides and is
well adapted, differences in haplotype structure in popu-
lations residing in geographically dispersed regions, such
as Uganda and South Africa, could lead to variable HLA
pathogen associations [19]. For example, HLA allele
polymorphisms HLA- B*5301, HLA- DRB1*1302, and
HLA- DRB1*0101 have been associated with genetic
resistance [20-22] or HLA-DRB1*04 with susceptibility
[23] to malaria, but the distribution is different in differ-
ent populations where malaria is endemic [19,20,24]. In
the study by, Alkharsah et al., [8], risk for KSHV shed-
ding in saliva was increased among carriers of HLA-
A*43, but this allele group was observed in 2.8% of
Table 2 Association between HLA alleles and KSHV DNA detection in saliva and peripheral blood among children in
the Uganda Sickle Cell Anemia KSHV Study, 2001-2002
Allele # KSHV DNA
positive/#KSHV
DNA negative
OR (95% CI) P-value # KSHV DNA
positive/#KSHV
DNA negative
OR (95% CI) P-value
Saliva
A priori-motivated analyses
Peripheral blood
HLA-A*30
Absent 20/121 1 26/130 1
At least 1 *3001 5/29 1.1 (0.5-4.3) 0.5 3/23 0.6 (0.2-2.2) 0.8
At least *3002 9/24 1.8 (0.8-4.1) 0.2 7/34 1.1 (0.5-2.7) 0.9
HLA-A*68
Absent 30/139 1 31/153 1
At least1*6801 0/6 0.0 0.6 1/5 1.0 (0.1-9.2) 1.0
At least1*6802 4/29 0.5 (0.1-1.8) 0.3 4/29 0.7 (0.2-2.3) 0.6
HLA-DRB1*04
Absent 32/173 1 34/187 1
At least 1*0405 1/3 1.8 (0.1-5.2) 0.5 2/2 5.5 (0.7-40.3) 0.1
Explorative analyses
HLA-B*08
Absent 31/160 1 29/176 1
At least 1*0801 3/14 1.1 (0.3-4.1) 0.9 7/11 3.9 (1.4-10.8) 0.01
HLA-B*44
Absent 30/165 1 33/176 1
At least 1*4403 1/6 1.1 (0.1- 9.9) 0.9 2/6 1.9 (0.3-9.1) 0.2
At least 1*4415 3/3 5.5 (1.1-28.6) 0.02 1/5 1.1 (0.1-9.2) 0.9
KSHV: Kaposi-sarcoma-associated herpesvirus; OR: odds ratio; 95% CI: 95% confidence interval; HLA-A, -B, -DRB1: Human leucocyte antigen -A, -B, -DRB1
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observed in our study and it was absent in another
study that evaluated HLA polymorphisms in Uganda
[17] and, thus, its effect cannot be replicated in Uganda.
Taken together, ours and Alkharsah’s study [8] provide
the first insights about HLA associations with KSHV
DNA shedding but additional studies are warranted to
clarify the role of host genetics in KSHV epidemiology.
The strengths of our study include assessment of HLA
polymorphisms on three loci among children and their
mothers. The pre-selected sample of children with sickle
cell disease, one time sampling of subjects and small
sample size were limitations. Thus, it is possible that
play of chance and multiple testing in small studies
could explain findings from both ours and Alkharsah’s
studies. Large and better designed studies are warranted
to evaluate the contribution of individual HLA poly-
morphisms to KSHV shedding in different populations.
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